Improving cardiovascular health of the most vulnerable

January 21, 2020

CHAPEL HILL, NC - Starting in 2016, a two-year partnership between the North Carolina Chapter of the American College of Cardiology (NCACC) and the North Carolina Association of Free and Charitable Clinics (NCAFCC) provided free lipid lowering therapy and clopidogrel to patients at seven free clinics in North Carolina. The results of this pilot study were recently published in the Journal of the American College of Cardiology.

"Through this pilot, we were able to increase the number of patients treated with statin medications, the number of statin medication tablets dispensed, and the use of high-intensity statins, resulting in significant decreases in total cholesterol and LDL levels," said Stouffer, who is the Ernest and Hazel Craige Distinguished Professor of Cardiovascular Medicine and chief of the division of cardiology.

"This shows the feasibility of a partnership between a medical specialty society and an association of free and charitable clinics, demonstrating the impact that a public health partnership can have on treating cardiovascular disease."

During year one, the seven clinics provided 1,296 patients with statin medications and dispensed a total of 178,384 tablets. During year two, the seven clinics provided 1,550 patients with statin medications, and dispensed a total of 279,474 tablets.

Altogether, the collaboration enabled more patients to receive statins (24% increase in year one and 45% increase in year two) and resulted in more statin tablets being dispensed (61% increase in year one and 83% increase in year two). In addition, there was an increase of 349% in the use of high intensity statin treatment in year one and a 38% increase in year two. In a random sample of 815 patients, who had lipid levels measured before and after initiation of the grant, total cholesterol decreased from 208 [173, 236] mg/dl to 175 [147, 209] mg/dl (p < 0.001), and LDL levels decreased from 120 [93, 147] mg/dl to 96 [71, 120] mg/dl (p < 0.001).

During the first year, the seven clinics provided 70 patients with clopidogrel (9854 tablets) and during the second year, the seven clinics provided 81 patients with clopidogrel (13,205 tablets).

"In this project, the North Carolina chapter of the American College of Cardiology was able to provide important cardiovascular medications to a group of vulnerable patients. Most of the patients who attend free clinics rarely, if ever, see a cardiologist. They usually only come to our attention when they get acutely ill and seek care in an emergency department. This project provides a model for specialty societies to improve the health of individuals who lack the resources to visit the specialist in their office."
Other project participants included William B. Abernethy, MD, FACC, James P. Zidar, MD, FACC, and B. Hadley Wilson, MD, FACC.

University of North Carolina Health Care

Related Clopidogrel Articles from Brightsurf:

Study reveals best anti-clotting strategy after heart valve intervention
The POPular TAVI trial has challenged current guideline recommendations on antiplatelet treatment after transcatheter aortic valve implantation (TAVI) in patients not taking oral anticoagulation.

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

Ticagrelor is as safe and effective as clopidogrel after heart attack
Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Stopping DAPT after one-month improved outcomes in stent patients
Patients who stopped taking aspirin one month after receiving a stent in the heart's arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.

Modern antiplatelet therapy: When is clopidogrel the right choice?
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp.

International study suggests combination therapy may prevent stroke in certain people
Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days.

Stroke prevention drug combo shows promise, study says
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine.

Ticagrelor has comparable safety to clopidogrel after heart attack
Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more potent blood thinner ticagrelor did not increase the risk of major bleeding (the primary endpoint) compared with the standard blood thinner clopidogrel, in a trial being presented at the American College of Cardiology's 67th Annual Scientific Session.

Read More: Clopidogrel News and Clopidogrel Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to